Phenotypic screens for bactericidal compounds against drug-resistant tuberculosis are beginning to yield novel inhibitors. However, reliable target identification remains challenging. Here, we show that tetrahydropyrazo [1,5-a]pyrimidine-3-carboxamide (THPP) selectively pulls down EchA6 in a stereospecific manner, instead of the previously assigned target Mycobacterium tuberculosis MmpL3. While homologous to mammalian enoyl-coenzyme A (CoA) hydratases, EchA6 is noncatalytic yet essential and binds long-chain acyl-CoAs. THPP inhibitors compete with CoA-binding, suppress mycolic acid synthesis, and are bactericidal in a mouse model of chronic tuberculosis infection. A point mutation, W133A, abrogated THPP-binding and increased both the in vitro minimum inhibitory concentration and the in vivo effective dose 99 in mice. Surprisingly, EchA6 interacts with selected enzymes of fatty acid synthase II (FAS-II) in bacterial two-hybrid assays, suggesting essentiality may be linked to feeding long-chain fatty acids to FAS-II. Finally, our data show that spontaneous resistance-conferring mutations can potentially obscure the actual target or alternative targets of small molecule inhibitors.
T uberculosis (TB), caused by Mycobacterium tuberculosis, is a global disease with an estimated 8.7 million new cases and around 1.4 million deaths annually 1 . TB drug resistance first emerged 40 years ago, but since then has grown to an alarming level, requiring the development of new antibiotics. Although enzyme-screening campaigns have dominated antibiotic discovery for years, their lack of success has prompted a change of strategy. In many instances, target identification of phenotypic hits is initiated by generating spontaneous drug-resistant mutants, with the expectation that resistance-conferring mutations will be revealed by whole genome sequencing (WGS) [2] [3] [4] [5] . For instance, Bedaquiline was identified as an inhibitor of the M. tuberculosis F 0 F 1 adenosine triphosphate (ATP) synthase through WGS of spontaneous resistant mutants 6 . Using the same approach, MmpL3 was shown to be targeted by several inhibitors including SQ109, adamantyl ureas, BM212, tetrahydropyrazo [1,5- (SPIROs) and indolcarboxamides [7] [8] [9] [10] [11] [12] [13] . However, spontaneous resistance can occur through mutations not only in the drug target, but also in other proteins linked to interactions between the cell and inhibitor 14, 15 . In this study we were able to exploit the stereoselectivity of ligand binding in a quantitative affinity pull-down to identify the target of THPPs and reveal a novel fatty acid shuttle in mycobacteria.
Results
Target identification. THPPs were prepared in a four-step synthetic route (Fig. 1a) , and the desired enantiomer was separated by chiral-HPLC. GSK366A and GSK951A 12 and two novel THPP analogues, GSK059A and GSK572A, were included as tool compounds for mode of action and structural studies. All compounds were endowed with selective anti-tubercular potency and were devoid of any significant cytotoxicity against HepG2 cell lines (Fig. 1b) . Compound GSK951A was progressed to a dose-response analysis in a murine model of chronic TB infection (Fig. 1c ) 12 . Thus, GSK951A combines potency in culture with in vivo activity and lack of cytotoxicity.
We applied a chemical proteomics strategy to identify the protein target(s) of the THPP lead compound directly in Mycobacterium bovis bacillus Calmette-Guérin (BCG) extracts. To this end, we synthesized carboxylic acid analogues of the active (GSK729) and inactive (GSK730) THPP enantiomers suitable for immobilization to Sepharose beads (Fig. 2) . Each type of bead was incubated with M. bovis BCG extracts under three different conditions: (1) in the presence of vehicle, (2) in the presence of excess 'free' active enantiomer analogue, and (3) in the presence of excess 'free' inactive enantiomer analogue. The relative protein content captured by the beads from each sample was quantified by isobaric tagging of tryptic peptides and tandem mass spectrometry analysis of the combined peptide pools in a 6-plex format 16 . Target proteins would be expected to bind selectively to beads derivatized with the active enantiomer analogue, a preference we probed by competition with free active versus free inactive enantiomers. Relative quantification (Supplementary Tables 1 and 2 ) demonstrated that only a single protein showed a pronounced preference in this competition assay. The putative enoyl-coenzyme A (CoA) hydratase EchA6 showed robust inhibition (92%) by the active enantiomer GSK729 to the binding of GSK729-derived beads, but only insignificant inhibition (16%) by its inactive enantiomer GSK730 (Fig. 2a,b) . MmpL3 was readily detected within the whole proteome analysis of the M. bovis BCG extract, but it was not identified in pull-downs with the immobilized THPP analogues. This does not necessarily rule it out as a target, as this result could be due to either steric hindrance by the linker on the compound, low affinity, or denaturation of the extracted MmpL3. Supporting the specificity of the GSK729-beads, in similar experiments performed with HepG2 cells, the beads did not capture the closest human EchA6 orthologue, ECH1. To determine the affinity of GSK729 for EchA6 in M. bovis BCG extracts, we optimized the concentration of immobilized ligands on the beads, enabling a dose-dependent binding of EchA6 to GSK729 in M. bovis BCG extracts with a half-maximum inhibitory concentration (IC 50 ) of 1.8 µM (Fig. 2c; Supplementary Tables 2  and 3). echA6 is essential and GSK951A inhibits mycolic acid biosynthesis. To confirm essentiality we used a genetic tool termed CESTET 17, 18 . Initially, a merodiploid strain in M. bovis BCG was generated that contained a second integrated copy of echA6 (Rv0905) under the control of the inducible tetracycline (ATc) promoter, and the genomic copy was subsequently disrupted. As shown in Supplementary Fig. 1a , the strain grew normally in liquid medium with ATc, but eventually showed cell lysis when grown in medium lacking ATc ( Supplementary Fig. 1a, inset) . To evaluate the effect of the depletion of echA6 on both mycolic acid and fatty acid synthesis in M. bovis BCG, mycolic acid methyl esters (MAMES) and fatty acid methyl esters (FAMES) were prepared from cultures following labelling with [ 14 C]-acetate. As shown in Supplementary  Fig. 1b , conditional depletion of echA6 results in a reduction of α-MAMES and keto-MAMES, while the overall abundance of FAMES remains largely unaffected, a classic hallmark of inhibitors targeting mycolic acid biosynthesis 14, 19 . In light of these findings, we decided to further investigate our previous studies on the effects of THPPs on mycolic acid synthesis 12 . As shown in Fig. 3a (left), GSK951A suppresses the synthesis of all classes of MAMES in M. bovis BCG, whilst the FAMEs remain largely unaffected. This result is similar to the mode of action of thiolactomycin (TLM) and isoniazid (INH), well-known inhibitors of mycolic acid biosynthesis 14, 19 ( Fig. 3a, right) , supporting our earlier echA6 conditional depletion experiments ( Supplementary  Fig. 1b ). Further resolution of the FAMES by reverse-phase thinlayer chromatography (TLC) indicated the accumulation of C26 FAMES (Fig. 3b) , suggesting that THPPs act downstream of fatty acid synthase-I (FAS-I), similar to the mode of action of INH (Fig. 3a,f ) . In addition, GSK951A significantly suppressed the synthesis of cell wall bound MAMES (Fig. 3a, middle) . In marked contrast, using the inactive enantiomer, GSK540A, even at a minimum inhibitory concentration (MIC) of 20× that of GSK951A, failed to inhibit total MAMES/FAMES and cell wall bound MAMES ( Supplementary Fig. 2 ). Whole-cell target engagement of GSK951A was supported by increased resistance when echA6 was overexpressed in M. bovis BCG. M. tuberculosis echA6 (Rv0905) was cloned into the multi-copy plasmid pVV16, which resulted in overexpression of His-tagged EchA6, as shown by western blot analysis (Fig. 3c) . On labelling cultures with [ 14 C]-acetate, pVV16-echA6 containing strains revealed an elevated synthesis of MAMES ( Supplementary Fig. 1c , left, and Supplementary  Fig. 1d ) and a sixfold increased resistance to GSK951A with solid or liquid media (MIC of 1.60-2.00 μM) when compared with the pVV16 vector control strain (MIC of 0.32 μM) ( Supplementary Fig. 1e and Fig. 3d) . Finally, the synthesis of cell wall bound MAMES in the pVV16-echA6 strain was less refractory to the addition of GSK951A at 1× MIC compared to the pVV16 vector control strain ( Supplementary Fig. 1c, right) .
The addition of GSK951A to cultures up to 4× the MIC resulted in no significant difference in terms of extractable cell envelope lipids ( Supplementary Fig. 3, A-D) . The organic solvent extractable mycolates were markedly altered in the presence of GSK951A and resulted overall in an elevated level of trehalose monomycolate (TMM) ( Supplementary Fig. 3 , D1 and D2). Indeed, confirmed MmpL3 inhibitors, including SQ109 and BM212, have been reported to cause significant accumulation of TMM 13 . Nevertheless, when applied at concentrations of up to 4× their respective MICs, SQ109 or BM212 had no effect on total MAMES Tables 1 and 2 ). c, Estimation of the affinity of GSK729 for EchA6 (Supplementary Table 3 ).
and only moderately inhibited cell wall bound MAMES (Supplementary Fig. 2 ). In contrast, GSK951A effectively suppressed both total and cell wall bound MAMES at concentrations well below the 4× MIC margin, emphasizing the distinctive phenotypic response of GSK951A. Interestingly, we have observed an increased sensitivity to GSK951A when MmpL3 (Rv0206c) was C]-Acetate labelling and doseresponse of GSK951A, INH and TLM against M. bovis BCG. Total MAMES and FAMES (a, left and right panels, n = 3 biological replicates), reverse-phase TLC (b, n = 2 biological replicates) and cell wall bound MAMES (a, middle panel, n = 2 biological replicates) were isolated, and equal counts for the former two, and an equal aliquot for the latter were analysed by TLC 13, 14, 30 . c, SDS-PAGE (left) and western blot (right) analysis of pVV16 and pVV16-echA6 cytosolic lysates (n = 3 biological replicates). d, Overexpression of M. tuberculosis EchA6 using pVV16-echA6 in M. bovis BCG (n = 5 biological replicates). e, Protein-protein interaction screen using the bacterial two-hybrid system BACTH and EchA6 with components of FAS-II (n = 3 biological replicates). f, Proposed biosynthetic model linking FAS-I, FAS-II and the β-oxidation pathways, providing a key role for EchA6 as a conduit for supplying acyl-CoA primers for mycolic acid biosynthesis. overexpressed in M. bovis BCG using the multi-copy plasmid pMV261-mmpL3, in comparison to the pMV261 vector control ( Supplementary Fig. 1f ). Increased sensitivity to GSK951A would be consistent with MmpL3 moonlighting as a THPP importer, in addition to its function as a TMM exporter. Taken together, these findings provide strong evidence for THPPs acting upstream of fatty acid synthase-II (FAS-II) (Fig. 3f ) , without excluding the possibility of a downstream activity via MmpL3. To further probe the possible interaction of EchA6 with components of FAS-II, we conducted a protein-protein interaction screen using the bacterial two-hybrid system BACTH. Interestingly, we found preliminary evidence for EchA6 interacting with two specific components of FAS-II (Fig. 3e,f ) . These included the β-ketoacyl-acyl carrier protein (ACP) synthase KasA and the enoyl-ACP reductase InhA (Fig. 3e) . No interactions were observed with other specific components of the core multi-enzyme FAS-II complex 20 .
Acyl-CoA and THPP ligand binding. Initial inspection of the sequence of EchA6 and related family members from M. tuberculosis indicated that the conserved carboxylate side chains 21 were mutated in EchA6, suggesting that EchA6, despite resembling an enoyl-CoA hydratase in overall sequence, was inactive. Nevertheless, residues involved in binding CoA are partially conserved in EchA6, leaving open the possibility that binding of acyl-CoAs was preserved, possibly as a mechanism for providing long-chain acyl-CoAs for fatty acid biosynthesis via FAS-II. Using intrinsic tryptophan fluorescence (ITF), we assayed variable chain-length acyl-CoA binding, which indicated that EchA6 has a clear preference for acyl-CoAs with chain lengths of 12 carbons or greater (Supplementary Table 4 and Fig. 4a ). Ligand binding assays using EchA6 and THPPs were conducted to establish the equilibrium dissociation constant (K d ) values for a selection of compounds (Supplementary Table 4 ), highlighting that GSK951A (Fig. 4b ) and GSK572A bound with the highest affinity, as reflected by K d values of 0.45 μM and 1.9 μM, respectively. In contrast, GSK573A, which is the inactive enantiomer of GSK572A, bound with a K d of 285.8 μM, a 150-fold increase, underscoring the distinct stereospecificity of the interaction between THPP compounds and EchA6 (Supplementary Table 4 ). Assessing C 20 -CoA binding following pre-incubation of EchA6 with GSK951A, at drug concentrations of 0.25 μM, 2.5 μM and 10 μM, resulted in a distinct weakening of the interaction with C 20 -CoA, thus indicating competition for the same binding site (Fig. 4c ). Similar experiments with C 4 -CoA (Fig. 4d) indicated that competition between acylCoA and GSK951A for the EchA6 binding site was not solely dependent on the acyl-chain. C 4 -CoA bound with less affinity than C 20 -CoA, and the K d increased by similar margins when competing with GSK951A (Supplementary Table 4 ). However, the increase was monotonic for C 4 -CoA, while raising GSK951A above 2.5 μM did not result in a further increase of K d for binding of C 20 -CoA. Finally, introducing the point mutation W133A, which maps to the THPP binding site (Fig. 6 ), completely abolished THPP binding (Fig. 4b ), whilst C 20 -CoA binding was weakened, but not abrogated (Supplementary Table 4 ).
In vivo target engagement of THPPs and EchA6. In an acute TB infection model 22 , M. tuberculosis transformed with a multi-copy plasmid-borne echA6 W133A resulted in a significant shift in the in vivo effective dose 99 (ED 99 ) of GSK951A when compared to strains transformed with empty vector or vector containing echA6 (Fig. 1d) . The echA6 W133A strain resulted in a significant increase in the ED 99 of GSK951A, from 85 and 77 mg kg -1 for the empty vector and echA6 strains, to >250 mg kg -1 for the echA6 W133A strain (Fig. 1d, right) . This increase of ED 99 was well outside the calculated 95% confidence interval (CI) for the empty vector and echA6 strains (41-182 mg kg -1 ). As a control, all strains had similar ED 99 values for INH (Fig. 1d, left) and were within the calculated 95% CI range (0.2-3 mg kg -1 ). Although the empty vector and echA6 strains were able to grow at the same rate when inoculated into C57BL/6 mice in the acute TB infection model, the echA6 W133A strain was relatively attenuated for growth (Fig. 1e) , suggesting that the viability of M. tuberculosis in vivo was compromised by the EchA6 point mutation that weakened acyl-CoA binding. In addition, M. bovis BCG transformed with a multi-copy plasmid-borne echA6 W133A and grown in broth showed a further increased resistance to GSK951A, with a MIC of 3.20 μM. This is in contrast to a M. bovis BCG strain transformed with plasmid-borne echA6, which had a MIC of 1.60 μM. Complete abrogation of THPP binding by EchA6 W133A would suggest a more pronounced effect; however, the wild-type copy present in the overexpressing strain could account for the modest MIC and ED 99 increase.
X-ray crystallographic analysis of EchA6. X-ray crystallographic structures of EchA6 in the ligand-free form, bound to C 20 -CoA and several THPPs, were determined by molecular replacement (Supplementary Table 5 ). EchA6 (Fig. 5a ) consistently crystallized as a trimer (Fig. 5b) , structurally resembling a flat disk with three extended substrate-binding grooves (Fig. 5c) . The binding sites of the CoA moiety and the THPPs reside on the 'front' and 'back' faces of the trimer, respectively (Fig. 5c ).
The EchA6 monomer is structurally similar to the rat liver enoylCoA hydratase (RnECH) 23 ( Fig. 5a,b and Supplementary Fig. 4a ). However, the C-terminal helices α10 and α11 diverge from the orientation seen in RnECH (Supplementary Fig. 4a ). In RnECH, the backbone turns 180°after helix α9, and helix α10 runs anti-parallel to α9, whereas in EchA6, helices α10 and α11 project forward and fold back onto the monomer (Fig. 5a ). Despite the altered backbone conformation, helices α10 and α11 still occupy analogous interfacial positions between the monomers in the context of the trimer (Fig. 5b) .
Enoyl-CoA hydratases belong to the crotonase superfamily of enzymes, which display diverse structural scaffolds and catalyse a wide variety of reactions involving CoA-linked substrates 24 . Among structural neighbours identified by distance matrix alignment (DALI) 25 , EchA6 aligns most closely with crotonases mediating enoyl-CoA hydratase activity (for example, RnECH, Supplementary  Fig. 4a ), in line with its annotation in sequence databases. Yet, the catalytic residues are not conserved in EchA6. The hydratase reaction converts the C2-C3 double bond of enoyl-CoA into a single bond and adds a hydroxyl to C3. Polarization is facilitated by positioning the acyl-keto oxygen against the amide nitrogens of nearby glycine and alanine residues (Gly141, Ala98 in RnECH), while two carboxylate side chains (Glu144, Glu164 in RnECH) coordinate the attacking water 21, 23 ( Fig. 5d ). Comparing the structures of EchA6 and RnECH (30.8% sequence identity), the oxyanion hole backbone amides are conserved (Ala100, Ala60), but the carboxylate side chains are substituted by glutamine (Gln103 for Glu144 of RnECH) and threonine (Thr123 for Glu164 of RnECH), respectively (Fig. 5d) . In contrast, the structural alignment of RnECH with M. tuberculosis EchA8 (PDB entry 3PZK, 50.2% identity) demonstrates complete conservation of key residues in the active site ( Supplementary Fig. 4b) . Nevertheless, the C 20 -CoA bound complex of EchA6 ( Supplementary Fig. 4c ) demonstrates a conserved mode of CoA-binding, with the thioester superimposing closely with the thioesters in the acetoacetyl-CoA bound complexes of RnECH (PDB entry 1EY3 21 ) and EchA8 (PDB entry 3Q0J). In addition, binding C 20 -CoA to EchA6 induces a conformational change in the β3-α3 loop (residues 61-68), transforming the substrate-binding groove into a tunnel between the 'front' and 'back' faces of the EchA6 trimer (green subunit in Fig. 5c ).
To define the structural determinants of THPP inhibition, we solved the structures of EchA6 in complex with five different THPPs (Supplementary Table 5 , Fig. 6a , and Supplementary  Fig. 4d-h ), including the lead compound GSK951A (Fig. 1a) . In the trimeric molecule, all three subunits are occupied by the ligand. Superposition of ligand-bound and apo structures reveals only minor conformational adjustments of side chains contacting the ligand. Situated on the 'back' face of the EchA6 trimer (Fig. 5c) , the inhibitor-binding site overlaps partially with the putative active site of EchA6 (marked by the conserved oxyanion hole of Ala100 and Ala60), but mostly occupies the extended hydrophobic groove, which accommodates the acyl-chain in the C 20 -CoA complex ( Fig. 5c and Fig. 6b ). The mode of binding is consistent in all THPP-complexed structures (Supplementary Table 5 and Supplementary Fig. 4d-h) . A slightly different ligand conformation is observed for GSK366A ( Supplementary Fig. 4f ), but the difference could be the result of different crystal symmetries (Supplementary  Table 5 ) due to packing-induced structural changes of the protein.
The complex with the bait compound, GSK729A, matches the binding mode of the other complexes ( Supplementary Fig. 4h ). Interactions with EchA6 are dominated by hydrophobic and van der Waals contacts. The pyrazolo-pyrimidine group is central to the interaction with the protein. The trifluoromethyl-substituent forms hydrogen bonds with His79 (to Nε2) and Gln103 (to Oε1 and Nε2), with an additional van der Waals contact to Ile76 (Cδ1) (Fig. 6c) . The ethylphenyl group forms hydrophobic contacts with Trp133, the β-carbon of Asp83 and the δ-carbon of Gln107 (Fig. 6c) . For GSK951A, the terminal benzodioxol group stacks on top of Phe216, with additional van der Waals contacts with the α-carbon of Lys213 and the β-carbon of Ala208.
Discussion
Target identification by stereoselective quantitative pull-downs points to EchA6 as the target of THPPs and is supported by a string of orthogonal evidence. This is in contrast to the recent target assignment of THPPs as MmpL3 12 , exposing an inherent weakness of target identification by WGS of THPP-resistant mutants. Resistance-conferring mutations against THPPs have not yet been observed in echA6; however, our targeted mutagenesis studies have induced resistance, which strongly supports THPPs acting through EchA6. The absence of SNPs in echA6 in spontaneous resistant mutants is not unexpected, because INH resistance is caused by mutations in inhA in only 2% of clinical isolates 26 . We demonstrate that THPPs potently suppress mycolic acid biosynthesis ( Fig. 3 and Supplementary Fig. 1 ). This phenotypic effect is distinct from other WGS-confirmed MmpL3 inhibitors, such as SQ109 13 and BM212 8 ( Supplementary Fig. 2 ). Previous studies have used high concentrations of MmpL3 inhibitors (ranging from 3× to 10× MIC) and it is conceivable that the significant accumulation of TMM may be a result of a stress response. However, the frequency of the MmpL3 resistance phenotype and the increased sensitivity to THPPs upon overexpression of mmpL3 gives credence to the possibility of MmpL3 moonlighting as a drug importer. Importantly, we demonstrate that echA6 is essential in mycobacteria and is conserved across several mycobacterial genomes (Supplementary Table 6 ), including the 'essential' minimal M. leprae genome 27 . Although the exact function of EchA6 remains to be established, we show that EchA6 has a distinct preference for long-chain acyl-CoAs and interacts with selective components of FAS-II. We postulate that EchA6 acts as a shuttle for fatty acid transfer, bypassing the non-essential FabH 28 . Overall, this would be compatible with its catalytically silent state, potential partners identified by STRING analysis (Supplementary Fig. 5 unidentified catalytic activity. Emerging from these considerations is a model (Fig. 3f ) that places EchA6 at a critical junction between FAS-I, β-oxidation and FAS-II pathways.
In conclusion, we have shown that THPPs mediate bactericidal activity in a mouse infection model of tuberculosis and that these compounds act on the catalytically silent enoyl-CoA hydratase-like EchA6 protein. This surprising result of our alternative target deconvolution approach suggests that spontaneous resistance-conferring mutations can potentially obscure the actual target or alternative targets of inhibitors emerging from phenotypic screening campaigns.
Methods
General information for chemical synthesis. Automated flash chromatography was performed on a Biotage FlashMaster II system with peak detection at 254 nm. LC-MS showed the desired product as major, and no starting material. After cooling to room temperature, the reaction mixture was diluted with TBME and washed with saturated NH 4 Cl aqueous solution and brine. The organic layers were concentrated and the residue was added to a silica gel column (5 g) and eluted with a mixture of EtOAc/cyclohexane (gradient 0-60%). Collection of the appropriate fractions afforded the desired racemic compound (116 mg, 0.296 mmol, 84%) as a white solid. The enantiomers were separated by semipreparative HPLC (flow, 18 ml min -1 ; solvent, hexane/EtOH 90/10; column, Chiralpak IC, 250 mm × 20 mm). The desired enantiomer eluted at 15 min and the opposite at 23 min. The title compound was obtained (35 mg, 0.089 mmol) as a white solid that was found to be enantiomerically pure by HPLC. in N,N-dimethylformamide (5 ml) at room temperature under nitrogen, HATU (269 mg, 0.707 mmol) was added followed by N,N-diisopropylethylamine (0.309 ml, 1.768 mmol). The mixture was stirred at room temperature for 15 min and then a solution of (5-fluoropyridin-2-yl)methanamine dihydrochloride (153 mg, 0.766 mmol) and N,N-diisopropylethylamine (0.309 ml, 1.768 mmol) in N,N-dimethylformamide (3 ml) was added. The mixture was stirred at room temperature for 3 days. The reaction mixture was diluted with EtOAc (30 ml) and washed with saturated aqueous NaHCO 3 (3 × 40 ml), water (40 ml) and 1 M NH 4 Cl (3 × 40 ml). The organic layer was dried, filtered and evaporated. The residue was added to a silica gel column and eluted with a mixture of EtOAc/cyclohexane (gradient 0-100%). Collection of the appropriate fractions afforded the desired racemic compound (221 mg, 0.469 mmol, 80%) as an off-white solid. The enantiomers were separated by semipreparative HPLC (flow, 18 ml min General experimentation. The measurement of the MIC for each tested compound, general antimicrobial activity, microsomal fraction stability, pharmacokinteic studies, HepG2 cytotoxicity assay, SDS polyacrylamide gel electrophoresis (PAGE) and western blot were performed as described previously 2, 19, 30 . EchA6 (Rv0905) was cloned into the mycobacterial multi-copy plasmid pMV261 and its derivatives 30 ; the site-directed mutant EchA6 W133A was generated using the plasmids containing wildtype echA6 and QuikChange II (Agilent Technologies). MmpL3 (Rv0206c) was cloned into pMV261. The constructs were electroporated into either M. bovis BCG or M. tuberculosis. The primers are described in Supplementary Table 7 . The in vitro effect of GSK951A, TLM and INH was studied by treating M. bovis BCG cultures at an optical density at 600 nm (OD 600 ) of 0.4 with inhibitor for 24 h, followed by [ 14 C]-acetate labelling for 24 h and subsequent analysis of either total FAMES and MAMES (equal counts, typically 30,000 c.p.m.), cell wall bound MAMES (equal volumes, 5% aliquot) or cell envelope lipids (equal counts, typically 30,000 c.pm.) as described previously 13, 14, 19, [30] [31] [32] . Protein-protein interactions were studied using the bacterial adenylate cyclase-based two-hybrid system as described previously 33 . Briefly, echA6 (Rv0905) was cloned using the primers described in Supplementary  Table 7 into pUT18 in-frame with the T18 fragment and the FAS-II genes were cloned into pKT25 in-frame with the T25 fragment. The positive control pKT25 was fused to the Leucine Zipper of GCN4 co-transformed with pUT18C of the Leucine Zipper GCN4. The negative control was pKT25 Zip co-transformed with empty pUT18 vector. The GSK in-house hydrophobicity assay was performed using 10 μl of a 10 mM DMSO stock solution diluted to 750 μl with octanol saturated phosphate buffer pH 7.4 and 160 μl buffer saturated octanol in a 96-well deep well block. Blocks were sealed and inverted for three sets of 50 inversions, then centrifuged at 300g for 20 min. Both phases were quantified using generic gradient UV-HPLC.
Assessment of chronic and acute efficacy in murine TB models. The assessment of the chronic and acute efficacy in murine TB models was performed using specific pathogen-free, 8-to 10-week-old female C57BL/6 mice purchased from Harlan Laboratories, which were allowed to acclimate for one week. In the chronic model, mice (n = 3-7 mice per dose level, a total of 27/28 mice per compound) were intratracheally infected with 100 colony-forming units (c.f.u.) per mouse and GSK951A formulated in 1% aqueous methylcellulose and administered daily for eight consecutive weeks, starting six weeks after infection. Lungs were collected 24 h after the last administration. All lung lobes were aseptically removed, homogenized and frozen. Homogenates were plated on 10% OADC-7H11 medium supplemented with activated charcoal (0.4%) for 18 days at 37°C. In the acute model 22 , mice were intratracheally infected with 50,000 c.f.u. per mouse with all strains, and lungs were collected on day 9. GSK951A and INH (in water) were administered daily for eight consecutive days, starting on day 1 after infection. All lung lobes were aseptically removed, homogenized, and plated in 10% OADC-7H11 medium supplemented with activated charcoal (0.4%) and grown for 18-25 days at 37°C. Lung log(c.f.u.) versus dose was fitted to a logistic equation (sigmoidal dose response, variable slope, GraphPad Prism software). ED 99 , defined as the dose in mg kg -1 that reduced lung bacterial burden at day 9 after infection by 99% (2 log(c.f.u.)) with respect to untreated, was calculated by interpolation in the sigmoidal curve. The number of mice was selected as the minimum number of mice necessary to detect a threefold difference in the ED 99 of two different products. Mice were randomly allocated to different experimental groups immediately after infection.
Preparation of M. bovis BCG cytosolic extract. M. bovis BCG cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 7.5% glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na 3 VO 4 , 1 mM DTT and one complete EDTAfree protease inhibitor tablet (Roche) per 25 ml). After sonication, the samples were adjusted to 0.8% Igepal-CA630 and extraction was completed by homogenization using a Dounce homogenizer. After 45 min rotation at 4°C, the samples were subjected to centrifugation for 10 min at 20,000g at 4°C. The supernatant was kept on ice, while the pellet was re-extracted with one volume of lysis buffer adjusted to 0.8% Igepal-CA630. The pellet was resuspended using a long 20 gauge needle (2×), followed by rotation for 30 min at 4°C. After a centrifugation step as described above, both supernatants were pooled and subjected to centrifugation at 100,000g for 1 h at 4°C. The final supernatant was snap frozen in liquid nitrogen and stored at −80°C.
Chemoproteomics. Sepharose beads were derivatized with GSK729A at various concentrations from 0.05 mM to 2 mM. Beads (35 µl) were washed and equilibrated in lysis buffer incubated at 4°C for 1 h with 1 ml (1 mg) M. bovis BCG cytosolic extract, which was pre-incubated with compound or buffer. Beads were transferred to disposable columns (MoBiTec), washed extensively with lysis buffer and eluted with SDS sample buffer. Proteins were alkylated, separated on 4-12% NuPAGE (Invitrogen), stained with colloidal Coomassie, and quantified by isobaric tagging and LC-MS/MS. Digestion, labelling with isobaric mass tags, peptide fractionation and mass spectrometric analyses were performed essentially as described in ref. 16 . The proteins.fasta file for M. bovis BCG was downloaded (11 May 2011) from http://genome.tbdb.org/annotation/genome/tbdb/ MultiDownloads.html and supplemented with the sequences of bovine serum albumin, porcine trypsin and mouse, rat, sheep and dog keratins. Decoy versions of all proteins were created and added. The search database contained a total of 11,492 protein sequences, 50% forward and 50% reverse. The criteria for protein quantification were a minimum of two sequence assignments matching to unique peptides (false discovery rate for quantified proteins ≪0.1%), a Mascot ion score of >15, a signal-to-background ratio of the precursor ion of >4 and a signal to interference of >0. 5 (ref. 34) . Reporter ion intensities were multiplied with the ion accumulation time, yielding an area value proportional to the number of reporter ions present in the mass analyser. Peptide fold changes were corrected for isotope purity as described and adjusted for interference caused by co-eluting nearby isobaric peaks as estimated by the signal-to-interference measure 35 . Protein quantification was achieved using a sum-based bootstrap algorithm 36 .
Generation and characterization of a conditional echA6 mutant in M. bovis BCG. A conditional mutant in the M. bovis BCG homologue of M. tuberculosis echA6 was generated using the genetic tool CESTET 17, 18 . First, a recombinant echA6 knockout phage was designed to replace the M. bovis BCG echA6 homologue. The primers used for amplifying the left and right flanks to generate the allelic exchange substrate 17, 18 are provided in Supplementary Table 7 . Rv0905 was then PCR amplified using the primers mdRv0905_F and mdRv0905_R (Supplementary Table 7 ) and cloned downstream of the tetracycline promoter into the integrating vector pTIC6a to generate the plasmid pTIC6a-Rv0905 17,18 . A merodiploid strain was then constructed by electroporating pTIC6a-Rv0905 into M. bovis BCG. The resultant strain BCG::Rv0905 was then transduced with echA6 knockout phage. Transductants were selected on 7H10-agar plates containing 25 μg ml -1 kanamycin, 75 μg ml -1 hygromycin and 50 ng ml -1 anhydrotetracycline (ATc). One confirmed knockout strain was called ΔBCG0957 and was used in a conditional depletion experiment to detect cell death, as shown previously in minimal medium 17, 18 .
Recombinant production and purification of EchA6 and EchA6
W133A
. The gene echA6 (Rv0905) was amplified by PCR (Supplementary Table 7 ) and cloned into plasmid pET28a (Novagen). Briefly, E. coli BL21 (DE3) transformed with pET28a-echA6 or pET28a-echA6 W133A (through site-directed mutagenesis of pET28a-echA6; the primers are described in Supplementary Table 7) were grown in Luria Bertani (LB) broth from a glycerol stock (37°C, 180 r.p.m., shaking), grown overnight and used to inoculate flasks containing 1 l of LB media containing 50 μg ml -1 kanamycin. Bulk cultures were grown (37°C, 180 r.p.m.), shaking to OD 600 = 0.4-0.6 and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside, reducing the incubation temperature to 16°C. Batch culture was continued at 16°C until 24 h postinduction, at which point cultures were collected by centrifugation at 5,000 r.p.m. at 4°C and the pellets were stored at -20°C. Cell pellets were defrosted and resuspended in 20 ml lysis buffer (50 mM sodium phosphate, 600 mM sodium chloride and 10 mM imidazole, pH 8) with a complete EDTA-free Protease Inhibitor Cocktail Tablet (Roche) and sonicated on ice with 10 cycles of 30 s sonication and 30 s cooling, and centrifuged (40 min, 15,000 r.p.m., 4°C). For purification of the His 6 -tagged EchA6 (and EchA6 W133A ) protein, a His-trap HP column (GE Healthcare Life Sciences) was used following the manufacturers guidelines, using a step-wise gradient of 50 mM, 125 mM, 150 mM and 200 mM imidazole in buffer. Eluates were analysed by 12% SDS-PAGE (Bio-Rad) run at 200 V, 50 mA for 40 min. Gels were stained with Instant Blue (Expedeon). Fractions containing pure protein were dialysed overnight in 2 l dialysis buffer (25 mM HEPES, 10% glycerol and 300 mM NaCl, pH 8). EchA6 was then concentrated by centrifugation to >30 mg ml -1 using a spin column (Thermo Scientific), and the concentration of protein was determined by absorption spectroscopy at 280 nm.
X-ray crystallographic structure determination. Crystals of EchA6 in the ligand-free form and bound to THPP compounds or C 20 -CoA were obtained by vapour diffusion at 18°C, using commercial sparse matrix screens JCSG-plus and MIDAS (Molecular Dimensions) in 96-well sitting drop plates (SWISSCI 3-lens). A liquid handling robot (Mosquito) was used to dispense 300 nl drops consisting of 150 nl protein at concentrations between 20 and 30 mg ml Table 5 . Data were reduced using XDS, XSCALE 37 and analysed using the CCP4 suite of crystallographic software 38 . Using M. tuberculosis EchA6 (PDB entry 3HE2) as a search model, we determined initial phases by molecular replacement (PHASER 39 ). The models were rebuilt and refined (COOT 40 , REFMAC5 41 , PHENIX.REFINE 42 ) using noncrystallographic symmetry restraints where the asymmetric unit contained three or six EchA6 subunits. Due to the limited resolution of the corresponding X-ray data, grouped B-factors were modelled when refining the complexes of EchA6:C 20 -CoA, EchA6:GSK059A and EchA6:GSK951A. Ligand geometry restraints were generated using the SKETCHER utility of CCP4 38 . Figures of the molecular structures of EchA6 were prepared using PyMOL (www.pymol.org). Refinement statistics are reported in Supplementary Table 5 . The Fo-Fc density maps ( Supplementary Fig. 4) indicating the presence and structures of the ligands were generated using phases of the protein model after initial refinement of the molecular replacement solution and prior to incorporation of the ligand in the coordinate model.
Intrinsic tryptophan fluorescence ligand binding assays. Fluorescence binding assays of EchA6 (3.75 µM) with acyl-CoAs were conducted on a Hitachi F7000 Fluorescence Spectrophotometer using 25 mM HEPES, 10% glycerol and 300 mM NaCl, pH 8 at 25°C, and fluorescence spectra were measured at an excitation wavelength of 280 nm and emission wavelength of 300-400 nm with an excitation and emission slit width of 5 nm using a 500 µl crystal cuvette. Ligands were added at increasing stoichiometric ratios ranging from 0.5 to 8 times the molar concentration of protein. DMSO concentrations were maintained at <0.6% and <2.0% in the assay mixture for acyl-CoA and THPP, respectively. Data were recorded using Hitachi FL Solutions 4.6 software and analysed in Prism 5 (GraphPad). To compare ligand binding between wild-type EchA6 and EchA6 W133A , the proteins were dialysed against buffer, 25 mM HEPES, 10% glycerol and 300 mM NaCl, pH 8, 2% DMSO (vol/vol). Changes of fluorescence intensities were corrected for volume expansion and for non-specific binding of DMSO.
